Principal Financial Group
VYGR icon

Principal Financial Group’s Voyager Therapeutics VYGR Stock Holding History

Principal Financial Group’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-74,000
Closed -$195K – 2652
2021
Q3 		$195K Sell
74,000
-554
-0.7% -$1.8K ﹤0.01% 2436
2021
Q2 		$308K Buy
74,554
+48,485
+186% +$220K ﹤0.01% 2346
2021
Q1 		$123K Buy
26,069
+1,992
+8% +$13.6K ﹤0.01% 2411
2020
Q4 		$172K Buy
+24,077
New +$231K ﹤0.01% 2321

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Principal Financial Group's VYGR Position: Q4 2021 in Review

Principal Financial Group sold out of Voyager Therapeutics (VYGR) in Q4 2021, closing a stake of 74,000 shares — an estimated $195K sold.

Principal Financial Group first reported a position in VYGR in Q4 2020 and held it in 4 quarters. The position peaked at $308K in Q2 2021. 59 funds tracked by Wall St. Rank hold VYGR as of Q4 2021.

  • Principal Financial Group reported no remaining Voyager Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 74,000 Voyager Therapeutics shares in Q4 2021, an estimated $195K.
  • Principal Financial Group first reported a position in Voyager Therapeutics in Q4 2020 and held it in 4 quarters.
  • Principal Financial Group's Voyager Therapeutics position peaked at $308K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.